Arbaclofen in Children and Adolescents with Autism Spectrum Disorder

Autism Spectrum Disorder is a disorder that has been defined by the medical community, but so far, none of the medications available for ASD treat the core symptoms of the disease, but rather secondary symptoms such as agitation or hyperactivity. Because ASD is genetically linked to Fragile X syndrome, researchers noticed that in a mouse model, the drug arbaclofen reduced what would be core symptoms of autism, such as combatting social avoidance and improving social function. A randomized placebo-controlled trial was conducted to test this idea and the results were recently published in Neuropsychopharmacology. Listen to the latest BrainPod to hear Dr. Jeremy Veenstra-VanderWeele discuss these results!

Hosted on Acast. See acast.com/privacy for more information.

More from NPP BrainPod

  1. 09:06Ghrelin decreases sensitivity to negative feedback and increases prediction-error related caudate activity in humans, a randomized controlled trialMay 06, 2024
  2. 09:08Spotlighting SHAPERS: Sex hormones associated with psychological and endocrine rolesMar 05, 2024
  3. 09:33Comparable roles for serotonin in rats and humans for computations underlying flexible decision-makingJan 04, 2024
  4. 09:58Integrating public health and translational basic science to address challenges of xylazine adulteration of fentanylOct 16, 2023
  5. 08:29The why, when, where, how, and so what of so-called rapidly acting antidepressantsSep 06, 2023
  6. 09:09AI-based analysis of social media language predicts addiction treatment dropout at 90 daysJun 23, 2023
  7. 09:27Oxytocin effects on amygdala reactivity to angry faces in males and females with ASPDApr 21, 2023
  8. 09:54To dismantle structural racism in science, scientists need to learn how it worksFeb 22, 2023
  9. 09:59Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activityDec 22, 2022
  10. 09:29Sex-dependent risk factors for PTSD: a prospective structural MRI studyNov 01, 2022